In Vivo (Add solvents to the product individually and in order.)
Homogeneous suspension
CMC-NA
≥5mg/ml
Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
Biological Activity
Description
Vinblastine sulfate inhibits microtubule formation and suppresses nAChR activity with IC50 of 8.9 μM in a cell-free assay, used to treat certain kinds of cancer. This compound induces autophagy and apoptosis.
Targets
nAChR (Adrenal Chromaffin Cells)
8.9 μM
In vitro
The average terminal half-lives of Vinblastine sulfate is 14.3 h. When incubated in freshly isolated rat hepatocytes, this compound penetrates rapidly and intensely into the cells, probably through a passive diffusion mechanism followed by tight cellular binding. It inhibits the angiogenic response induced by adrenomedullin and is also positive for mitotic slippage, causing micronuclei in mononucleate cells with cytokinesis block. This chemical gives significant increase in micronucleated mononucleated cells at concentrations that produced approximately 50% cell death and cytostasis or less as calculated using RPD, RICC and RCC.
In Vivo
Vinblastine is a widely used anticancer drug with undesired side effects. A combination of this compound and RAP at very low doses against human HCC gets a satisfactory antiangiogenic effect in vivo. The clinically relevant dose of this chemical inhibits palmitoylation of tubulin in vivo in CEM cells (effect on depalmitoylation of tubulin).
Six-well treatment plates are set up that contained 5 × 104 cells/mL in each well, suspended in 3 mL culture medium, and these are treated with this compound for 3 h followed by 21 h growth.
References
https://pubmed.ncbi.nlm.nih.gov/8516349/
https://pubmed.ncbi.nlm.nih.gov/19666138/
https://pubmed.ncbi.nlm.nih.gov/2088769/
https://pubmed.ncbi.nlm.nih.gov/14508526/
https://pubmed.ncbi.nlm.nih.gov/17202812/
Sellecks Vinblastine sulfate Has Been Cited by 46 Publications
Induction of cell death by the CXCR2 antagonist SB225002 in colorectal cancer and stromal cells
[ Biomed Pharmacother, 2025, 188:118203]
Eribulin Induction of Immunogenic Cell Death (ICD): Comparison With Other Cytotoxic Agents and Temporal Relationship of ICD Biomarkers
[ Anticancer Res, 2025, 45(1):39-53]
A BPTF Inhibitor That Interferes with the Multidrug Resistance Pump to Sensitize Murine Triple-Negative Breast Cancer Cells to Chemotherapy
[ Int J Mol Sci, 2024, 25(21)11346]
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.
